First-line sunitinib cost-effective alternative to interferon-α in renal cancer
NICE not so bad after all?
Cost studies still not being used at all levels of decision-making
HPV vax still igniting debate
Economic analysis of antidepressants from ICPE
Inappropriate therapy for MRSA costly, potentially deadly, problem
Medicare health web site difficult to use
Empirical aciclovir cost effective for some neonatal HSV cases
HPV vaccination ± screening could be valuable in India
Improved oxygen systems decrease mortality in childhood pneumonia
Drug warnings fail to decrease antipsychotic use in elderly
Measles increase a result of vaccine scare, says US CDC
Only a fraction of patients with diabetes mellitus undergoing PCI* for NSTE-ACS** in Europe receive GPIIb-IIIa antagonists,
Increasing co-payments may worsen health disparities
Modified guidelines prove effective in childhood pneumonia
More employers are looking to consumer-driven health plans and employee wellness programmes
The combination of two existing, inexpensive drugs may offer new hope
The under-use of β-blockers for treating chronic heart failure (HF) might be explained by the deteriorations associated with advanced disease.
California's tobacco control programme saved $US86 billion (2004 values) in personal healthcare costs
Combined HRT improves HRQOL in older women
Lawmakers hone in on drug price hikes
Pharmacogenomics-based drug development provides hope
Previous studies have demonstrated the reliability of the Psoriatic Arthritis Quality of Life tool (PsAQoL)
Generic drug stores for India's poor
US FDA sets its sights on the developing world
Lidocaine 5% medicated plaster [Versatis] has been approved for restricted use within the NHS Scotland
Medical bills and debts are affecting 79 million adults in the US,
Bayer Schering, Germany, has announced it will support the US Agency for International Development (USAID)
Novartis has announced that the final National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance
Decision Resources has forecast that the hepatitis B drug market in China will more than double by 2012,
Russia will enter the top 10 global pharmaceutical markets in 2008,
Sharing of prescription medications is common practice among over one-third of women of reproductive age,